drugset / Trial / NCT00099749

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

NCT00099749

Phase 2/3 Completed 255 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.

Timeline

Start
2003-11
Primary completion
2006-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 2.5 mg
Subject Fingolimod Small molecule 5 mg

Indications

No indication recorded.